Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: A phase II study

Purpose: This phase II study was conducted to evaluate the efficacy and tolerability of vinorelbine (navelbine) and oral VP-16 (etoposide) in pretreated metastatic breast cancer (MBC) patients. Patients and methods: Twenty-two female patients with therapy-resistant metastatic breast cancer were treated with vinorelbine 25 mg/m² i.v. on days 1 and 8 and oral VP-16 50 mg/m²/day for 14 days. Cycles were repeated every 28 days. Treatment was given until clear evidence of disease progression. Results: Complete remission was observed in 3 (14%) patients, and partial remission or stable disease in 10 (45%) patients. Median duration of response was 4 months (range 2-8). Symptomatic improvement, irrespective of imaging methods results, as evaluated through improved performance status (PS), the lack of requirement for urgent palliative radiotherapy, and a decrease in steroids and analgesics doses was demonstrated in 10 (45%) patients through a special questionnaire completed by all patients. Side effects were manageable. Dose modification due to leucopenic fever were necessary in only 3 patients. Previous radiation therapy did not mitigate the application of full doses of chemotherapy. Conclusion: Vinorelbine/VP-16 combination is active and tolerable in relapsed and heavily pretreated MBC patients.